SG/CALL/NOVO-NORDISK B/1140/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 05:03:54 2024-05-22 EDT | ||
| 0.51 EUR | -5.56% |
|
| Current month | -6.90% | ||
| 1 month | +12.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 0.51 | -5.56% |
| 24-05-21 | 0.54 | +5.88% |
| 24-05-20 | 0.51 | +6.25% |
| 24-05-17 | 0.48 | -5.88% |
| 24-05-16 | 0.51 | -5.56% |
Real-time Boerse Frankfurt Warrants
Last update May 22, 2024 at 05:03 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7HUX |
| ISIN | DE000SW7HUX1 |
| Date issued | 2024-03-11 |
| Strike | 1,140 kr |
| Maturity | 2024-12-20 (213 Days) |
| Parity | 10 : 1 |
| Emission price | 0.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.85 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.01 € |
| Spread % | 1.92% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
927.2
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.94%
- Stock Market
- Warrants
- Warrant
